Wells Fargo has reiterated its 'Overweight' rating on Viridian Therapeutics and increased its price target from $31 to $34. This adjustment suggests a potential 17.0% upside from the stock's closing price on November 4, 2026, indicating a positive outlook from the analyst firm.
Wells Fargo's decision to maintain an 'Overweight' rating and raise the price target for Viridian Therapeutics (VRDN) to $34 from $31 signals continued confidence in the company's prospects. This 9.7% increase in the price target, implying a 17.0% upside, is a positive signal for investors. It suggests that the analyst firm believes VRDN's valuation has room to grow, potentially driven by pipeline developments or market positioning. For traders, this could lead to short-term upward momentum as investors react to the positive analyst sentiment, offering an opportunity for those looking to capitalize on analyst upgrades.